Tonix Pharmaceuticals Has Enrolled The First Participant In Phase 2 'POWER' Study Of TNX-1900 (Intranasal Potentiated Oxytocin) For Pediatric Obesity At The Massachusetts General Hospital
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has enrolled the first participant in its Phase 2 'POWER' study of TNX-1900, a treatment for pediatric obesity, at the Massachusetts General Hospital.
July 10, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals has started its Phase 2 'POWER' study of TNX-1900, which could potentially impact the company's stock positively if the study yields positive results.
The initiation of a Phase 2 study is a significant milestone for any pharmaceutical company. Positive results from this study could potentially lead to a surge in the company's stock price. However, it's also important to note that the results of the study are uncertain and could also negatively impact the stock if they are not favorable.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100